215917-98-9

Basic information

• Product Name: (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate
• Synonyms: (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate;(R)-MethylN-tert-butoxycarbonylMorpholine-3-carboxylate;3-(S)-Methoxycarbonyl-4-tbutoxycarbonylMorpholine;(3S)-3,4-Morpholinedicarboxylic acid 4-(1,1-dimethylethyl) 3-methyl ester;(S)-4-(tert-butoxycarbonyl)-3-MethylMorpholine-3-carboxylic acid;4-(tert-butyl)3-methyl(S)-morpholine-3,4-dicarboxylate;(S)-tert-butyl methyl morpholine-3,4-dicarboxylate;METHYL (S)-4-BOC-MORPHOLINE-3-CARBOXYLATE
• CAS NO: 215917-98-9
• Molecular Formula: C11H19NO5
• Molecular Weight: 245.27226
• Mol File: 215917-98-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate(215917-98-9)
• EPA Substance Registry System: (S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate(215917-98-9)

Safety Data

• Hazardous Substances Data: 215917-98-9(Hazardous Substances Data)

Usage

General Description

(S)-4-tert-butyl 3-Methyl Morpholine-3,4-dicarboxylate is a chemical compound that belongs to the class of morpholine derivatives. It is a chiral molecule with two stereocenters, giving rise to two enantiomers. It is commonly used in the field of organic synthesis and pharmaceutical research due to its versatile reactivity and potential biological activity. The presence of the tert-butyl and methyl groups on the morpholine ring makes it a valuable building block for the synthesis of various complex organic molecules. Additionally, its unique structure and stereochemistry make it a promising candidate for the development of novel drug molecules with potential therapeutic applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1235387-14-0 C₁₃H₁₇NO₃ 
• 67-56-1 methanol 
• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 106825-79-0 (S)-morpholine-3-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 1447972-26-0 methyl (3S)-morpholine-3-carboxylate hydrochloride 
• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 

Relevant articles and documents

Preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid

The invention provides a preparation method of chiral N-tert-butyloxycarborylmorpholine-3-carboxylic acid, which comprises the following steps: (1) carrying out an amino protection reaction on chiralserinamide and an amino protective agent to obtain a com

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from(a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16,(e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and(g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, ?and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5—(d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.